Skip to content

Current Debt at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$19.3M+72.4%
AbbVie logo
AbbVieABBV
$0-100%
Incyte logo
IncyteINCY
$4.41M-1.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.31B-35.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Alkermes logo
AlkermesALKS

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's current debt?
Aurinia Pharmaceuticals (AUPH) reported current debt of $16.52M in Q1 2026.
How has Aurinia Pharmaceuticals's current debt changed year-over-year?
Aurinia Pharmaceuticals's current debt increased by 13.9% year-over-year, from $14.51M to $16.52M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.